Modafinil

modafinil

Modafinil is the smartest of the wakefulness drugs — a Schedule IV eugeroic that delivers stimulant-like alertness without the dopaminergic spike of amphetamines. For narcoleptics it is life-changing. For high performers it is a calculated tool, not a daily crutch.

Wakefulness-promoting agent (eugeroic)Prescription requiredEvidence A
⚠ Not medical advice.Not medical advice. This page is educational. Discuss with your physician before starting, changing, or stopping any medication.

Why it matters

Modafinil occupies a unique pharmacological niche. It is not an amphetamine, not a nootropic supplement, and not a substitute for sleep — yet for shift workers, jet-lagged executives, and people recovering from acute sleep loss, the cognitive lift is real and reproducible. The 2015 Battleday meta-analysis of cognitive enhancement studies in healthy adults concluded modafinil reliably improves executive function, attention, and learning on complex tasks, with effects most pronounced in sleep-deprived states. What makes modafinil interesting for the performance-medicine audience is what it does not do: it does not produce the dopaminergic rush, crash, or addiction trajectory of Adderall. The tradeoff is that it is also less euphoric and less effective at brute-forcing motivation. Used 1-3 days per week as a targeted tool — long-haul travel, post-overnight surgical recovery, time-zoned deals — it can be one of the highest-leverage prescriptions in the cognitive medicine catalog. Used daily as a Band-Aid over poor sleep hygiene, it accelerates decline.

Uses

Label uses (approved)
  • Narcolepsy with or without cataplexy
  • Shift work sleep disorder (SWSD)
  • Excessive daytime sleepiness in obstructive sleep apnea (as adjunct to CPAP)
Off-label (educational only)
  • Cognitive enhancement in sleep-deprived adultsmoderate
  • ADHD (off-label, second-line)weak
  • Fatigue in depression / MS / chemotherapymoderate
  • Jet lag recoveryweak

Dosing

Label dose
200 mg once daily in the morning (narcolepsy/OSA); 150-200 mg 1 hour before shift (SWSD).
Off-label / biohacker dose
Off-label cognition: 100-200 mg in the morning, no more than 3-4 days per week to limit tolerance and sleep debt.
Titration: Start at 100 mg to assess tolerance. Avoid afternoon dosing — half-life is 12-15 hours and late doses wreck sleep architecture. Do not stack with caffeine for first dose.
When to take: Morning, immediately upon waking. Never after 12 PM.

Side effects & warnings

Common
  • Headache
  • Nausea
  • Insomnia
  • Anxiety
  • Dry mouth
  • Decreased appetite
Uncommon but serious
  • Palpitations
  • Mild blood pressure elevation
  • Irritability
  • Skin rash
Serious warnings
Rare but serious: Stevens-Johnson syndrome and toxic epidermal necrolysis (discontinue immediately if any rash). DRESS syndrome reported. Psychiatric reactions including mania and psychosis in susceptible patients. Reduces effectiveness of hormonal contraceptives via CYP3A4 induction.

Biomarkers affected

blood pressure
variable
Mild increase in systolic and diastolic BP (typically 5-10 mmHg systolic); avoid in uncontrolled hypertension or recent MI.
Evidence: weak
cortisol am
variable
Modafinil blunts the normal evening cortisol decline and can slightly elevate AM cortisol; clinical significance is small in healthy users.
Evidence: weak
resting hr
variable
Modest increase in resting heart rate (typically 5-8 bpm); larger in caffeine co-users and patients with autonomic dysregulation.
Evidence: weak

Monitoring

Baseline blood pressure and heart rate; reassess at 1 month. Liver function panel annually with chronic use. Sleep quality tracking is essential — modafinil masks but does not replace sleep.

The honest risk picture

## Serious Risks **Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)** are rare but life-threatening. Any rash that develops within the first 1-3 months of starting modafinil is a medical emergency — discontinue immediately and seek care. The FDA-mandated black-box-adjacent warning is real, not theoretical. **Psychiatric reactions** including mania, psychosis, and suicidal ideation have been reported, particularly in patients with underlying bipolar disorder or psychosis history. Screen carefully before prescribing. **Cardiovascular effects** are typically mild (5-10 mmHg systolic BP increase, 5-8 bpm heart rate increase) but can be clinically significant in patients with hypertension, arrhythmia, or recent MI. Avoid in left ventricular hypertrophy. ## Practical Cautions - **Hormonal contraceptive failure:** Modafinil induces CYP3A4 and can reduce oral contraceptive efficacy for up to 1 month after discontinuation. Backup contraception is required. - **Tolerance:** Daily use rapidly produces tolerance to the cognitive lift. Cycle 2 days on, 1-2 days off — or reserve for targeted high-leverage days. - **Sleep debt accumulates invisibly.** Subjective alertness on modafinil does not reflect underlying recovery state. HRV, resting heart rate, and mood collapse before the user notices. - **Drug interactions:** Reduces effectiveness of cyclosporine, theophylline; increases levels of TCAs, warfarin, and some SSRIs.

Practical context

Cost (US, retail)
$35/mo
Legality
Schedule IV controlled substance in the US. Prescription-only in EU, UK, Canada, Australia. Personal-use importation policies vary.
Interactions
true

FAQ

Is modafinil addictive?+
Modafinil has lower abuse liability than amphetamines but is not non-addictive. The DEA classifies it as Schedule IV. Psychological dependence can develop with daily use.
Will modafinil replace sleep?+
No. Modafinil suppresses the subjective feeling of sleepiness but does not restore the cognitive, immune, and hormonal functions of real sleep. Chronic use as a sleep substitute is harmful.
Can I drink coffee on modafinil?+
Small amounts are tolerable but the combination amplifies anxiety, jitters, and blood pressure. Most experienced users skip coffee on modafinil days.
Does modafinil work for ADHD?+
Evidence is mixed and weaker than for stimulants. The FDA rejected pediatric ADHD indication in 2006 due to safety concerns including SJS.
References (4)+
  1. .
  2. .
  3. .
  4. .
The prime report

Weekly performance intelligence.

New studies, protocols, and optimization frameworks delivered every Monday. No fluff, no motivation quotes — only what moves the needle.

No spam. Unsubscribe anytime.